Amgen Builds Up Future Launches As Oncology Biosimilars Slide
Firm Looks To Amjevita, Along With Stelara And Eylea Rivals, For Future Growth
• By David Wallace
As Amgen’s oncology biosimilars decline, a lift will come from new products • Source: Shutterstock 
